27 April 2026
Latham & Watkins Advises Ascendis Pharma on Nasdaq Ordinary Share Listing
Advising firms
No advising firm is named in this release.
Deal team
0 lawyers named in this releaseNo individual lawyer is named in this release.
Stated terms
The stated value, client and counterparties is part of full access
Full access opens the figure exactly as the release prints it, what that figure measures, the client and the counterparties, each with the sentence it came from.